Chronic Myeloid Leukemia - Accelerated Phase
4
2
2
0
Key Insights
Highlights
Treatment Research
7 treatments under study, led by Cyclophosphamide
Research Leaders
5 sponsors active, led by University of Florida
Related Conditions
Often studied with 11 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (4)
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML
Research Network
Common Treatments
- Cyclophosphamide1
- Busulfan Conditioning For Allo Transplant1
- Fludarabine Fludara1
- Intensity Modulated Total Marrow Irradiation1
- Based Decitabine And Olverembatinibhqp1351chemotherapy1
Active Sponsors
- University of Florida1
- Orca Biosystems, Inc.1
- Ascentage Pharma Group Inc.1
- Nanfang Hospital, Southern Medical University1
- University of Illinois at Chicago1
Top Investigators
Peking University People's Hospital
Peking University People's Hospital
University of Florida
University of Illinois at Chicago
Related Conditions
- Chronic Myeloid Leukemia In Myeloid Blast Crisis2
- Acute Lymphoid Leukemia1
- Chronic Myeloid Leukemia In Lymphoid Blast Crisis Diagnosis1
- Myelodysplastic Syndromes1
- Acute Myeloid Leukemia Relapsed Adult1